ClinicalTrials.gg
WithdrawnNCT02388529Updated Oct 15, 2015

A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Bendavia™ (MTP-131) in Patients With Heart Failure

A Phase 1 interventional study of MTP-131 and MTP-131 in Heart Failure, sponsored by Stealth BioTherapeutics Inc.. Withdrawn at 1 site in Bulgaria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-10-15.

Sponsored by Stealth BioTherapeutics Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 82 studies in Heart Failure with a site in Bulgaria — 18 open to participants now, 22 under way, 12 of them phase 3. Heart Failure · Bulgaria.

Enrollment
76th of 76
0 · median 617
Started
2015
the only one that year
Phase 1
4 of 82
none open now
Registered
20th of 82
by date
Lead sponsor
3 of 82
Stealth BioTherapeutics Inc.

Among the 82 studies in Heart Failure with a site in Bulgaria, this one is the 76th largest by enrollment of the 76 interventional ones that give a count, is the only one that started in 2015, is one of 4 in phase 1, and was the 20th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

18 of the 82 studies in Heart Failure with a site in Bulgaria are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in Bulgaria have not opened yet or have stopped. Only those recruiting at a site in Bulgaria →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Heart Failure with a site in Bulgaria, or all of them as a file.
02

Study summary

This study is a single-center, randomized, double-blind, placebo-controlled study in patients with stable heart failure to evaluate the safety, tolerability, pharmacokinetics, and efficacy of multiple ascending doses of Bendavia™ (MTP-131) intravenous infusion.

03

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • Heart Failure
  • Bendavia™
  • MTP-131
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≤45% by 2-D echocardiogram.
  • Diagnosis of Class II or III HF for a minimum of 6 months prior to the Screening Visit.
  • HF is considered to be stable, in the judgment of the Principal Investigator and no hospitalization related to HF has occurred within the 1 month prior to the Screening Visit.
  • Treatment with appropriate pharmacologic therapy for HF including, but not limited to, angiotensin converting enzyme inhibitor (ACEI) and/or angiotensin receptor blocker (ARB), and an evidence-based beta blocker for the treatment of HF
  • Females of must have a negative serum pregnancy test at the Screening Visit.
  • Written obtained that strictly adheres to the written guidelines from the local Ethical Committee (EC).

Exclusion criteria

Exclusion Criteria:

  • Unstable angina pectoris within 1 month before initiation of screening procedures. Unstable angina is defined as the occurrence of chest pain more frequently than usual, pain at rest or upon minimal exertion, or protracted episodes of pain without any discernible trigger, and/or chest pain that persists despite use of vasodilatory therapy (e.g., nitroglycerin).
  • Coronary or peripheral artery revascularization procedure within 2 months prior to the Screening Visit.
  • An acute myocardial infarction within 3 months prior to the Screening Visit.
  • Supine resting heart rate ≥ 100 beats per minute after 5 minutes rest.
  • Uncontrolled hypertension defined as a systolic blood pressure (BP) >180 mm Hg or a diastolic BP >110 mm Hg on at least 2 consecutive readings.
  • Requirement for valve or other cardiac surgery (e.g., pericardectomy).
  • Cardiac surgery or valvuloplasty within 2 month prior to the Screening Visit.
  • General surgery within 1 month prior to the Screening Visit.
  • Restrictive cardiomyopathy, obstructive cardiomyopathy, pericardial disease, amyloidosis, infiltrative cardiomyopathy, uncorrected thyroid disease, or dyskinetic left ventricular aneurysm.
  • Cerebrovascular accident or within 3 months prior to the Screening Visit.
  • Liver enzyme ( [ALT] and/or aspartate aminotransferase [AST]) elevation >3x the (ULN).
  • Estimated (eGFR) \<30 mL/min, using the Modification of Diet in Renal Disease (MDRD) Study equation.
  • Known active drug or alcohol abuse.
  • Active infection requiring systemic treatment or surgical intervention.
  • Significant acute or chronic medical or psychiatric illness that, in the judgment of the Investigator, could compromise subject safety, limit the subject's ability to complete the study, and/or compromise the objectives of the study.
  • Female patients who are pregnant or breastfeeding.

    • Other protocol-defined inclusion/exclusion criteria may apply.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Low dose

    Drug: MTP-131

  • Experimental
    Intermediate dose

    Drug: MTP-131

  • Experimental
    High dose

    Drug: MTP-131

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • MTP-131 (low dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days

  • MTP-131 (intermediate dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days

  • MTP-131 (high dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days

  • DrugPlacebo

    Placebo Comparator (at each dose cohort) administered as once-daily 1- hour intravenous infusion for 5 consecutive days

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events

    Time frame: Assessed up to Day 33

  2. Mean peak plasma concentration (Cmax) of MTP-131 (ng/ml) in each cohort

    Time frame: Assessed up to Day 12

Secondary outcomes

  1. Changes in echocardiographic LV end-systolic volume (LVESV)

    Time frame: Assessed up to Day 33

07

Study locations

1 site
  • Sevlievo, Gabrovo, Bulgaria
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2015, a primary completion of Sep 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2015
First posted
Mar 17, 2015
Start
May 2015
Primary completionEst.
Sep 2015
CompletionEst.
Oct 2015
Last update
Oct 15, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02388529
Responsible party
Sponsor
First posted
Mar 17, 2015
Start date
May 2015
Primary completion
Sep 2015 (estimated)
Completion
Oct 2015 (estimated)
Last update
Oct 15, 2015

Study contacts

Jim Carr, PharmD
study director · Stealth BioTherapeutics Inc.
Sotir Marchev, MD,PhD, FESC
principal investigator · Bulgaria

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elamipretide

Start the discussion